The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Isaeva G.K.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Andrievskih M.I.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Berseneva O.V.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Shubina K.A.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Taskina D.K.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Erygina A.A.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Maltseva V.A.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Bakhareva I.V.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Menshchikov D.V.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

The effectiveness of combined chemotherapy and immunotherapy, and the search for personalized approaches to treating advanced non-small cell lung cancer

Authors:

Isaeva G.K., Andrievskih M.I., Berseneva O.V., Shubina K.A., Taskina D.K., Erygina A.A., Maltseva V.A., Bakhareva I.V., Menshchikov D.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2025;14(4): 37‑45

DOI: 10.17116/onkolog20251404137

Read: 776 times

Buy for 300₽
Contact the author
Table of contents

THE EFFECTIVENESS OF COMBINED CHEMOTHERAPY AND IMMUNOTHERAPY, AND THE SEARCH FOR PERSONALIZED APPROACHES TO TREATING ADVANCED NON-SMALL CELL LUNG CANCER
THE EFFECTIVENESS OF COMBINED CHEMOTHERAPY AND IMMUNOTHERAPY, AND THE SEARCH FOR PERSONALIZED APPROACHES TO TREATING ADVANCED NON-SMALL CELL LUNG CANCER

To cite this article:

Isaeva GK, Andrievskih MI, Berseneva OV, et al. The effectiveness of combined chemotherapy and immunotherapy, and the search for personalized approaches to treating advanced non-small cell lung cancer. P.A. Herzen Journal of Oncology. 2025;14(4):37‑45. (In Russ.)
https://doi.org/10.17116/onkolog20251404137

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Mediastinal staging in planning the mana­gement of patients with non-small cell lung cancer. P.A. Herzen Journal of Onco­logy. 2025;(2):57-63
Effi­cacy of chemoimmunotargeted therapy in patients with adva­nced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Onco­logy. 2025;(3):63-70
Resu­lts of the use of immune checkpoint inhi­bitors in the treatment of small cell lung cancer in real-life clinical practice: resu­lts of a single-center obse­rvational study. P.A. Herzen Journal of Onco­logy. 2025;(4):46-53
Main trends in the epidemiology of mali­gnant neoplasms in the Sibe­rian Fede­ral district. P.A. Herzen Journal of Onco­logy. 2025;(4):61-68
Clinical and economic analysis of nutritional support in the perioperative treatment of lung cancer. P.A. Herzen Journal of Onco­logy. 2025;(5):54-58
Nece­ssary and sufficient dose at stereotactic radiotherapy in functionally inoperable patients with non-small cell lung cancer. P.A. Herzen Journal of Onco­logy. 2025;(6):7-12
Morphological examination of surgical mate­rial of primary lung cancer after neoadjuvant therapy: reco­mmendations and lite­rature review. Russian Journal of Archive of Pathology. 2025;(4):40-46
Use of fari­cimab in neovascular age-related macu­lar dege­neration and diabetic macu­lar edema in Russia. Resu­lts of the FARWATER retrospective study. Russian Annals of Ophthalmology. 2025;(6):82-91
Expe­rience of Rela­tox (botulinum toxin type A) using for chro­nic migraine treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):134-140
Abstract:

Lung cancer is one of the most significant health problems globally due to its high prevalence and mortality rates. Innovative treatment regimens are needed to improve survival rates and reduce mortality from this disease in clinical practice.

OBJECTIVE

To evaluate the effectiveness and safety of a combination therapy consisting of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) in the treatment of advanced non-small cell lung cancer (NSCLC). We also aim to identify the optimal patient population for whom this treatment regimen would be most beneficial in real-world clinical practice.

MATERIAL AND METHODS

A retrospective analysis of the medical records of 58 patients who received a combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) at medical institutions in the Chelyabinsk region between January 2020 and November 2023 was conducted.

RESULTS

The median age of the 58 participants was 62 years (range: 38—84). The median duration of ABCP treatment was 11.3 months. Disease control (partial response or stable disease) was achieved in 84.2% (48) of patients. The median progression-free survival was 15.1 months (95% confidence interval (CI): 11.7—20.3). The mPFS among patients with brain metastases was 24.8 months (95% CI: 19.2—40.7)), p=0.05, and the median overall survival has not been reached yet.

CONCLUSION

The study demonstrated that ABCP therapy shows high antitumor efficacy in real-world clinical settings for patients with advanced NSCLC. The objective response rate and progression-free and overall survival were equivalent or superior to those observed in the IMpower150 study. A subgroup analysis showed that patients with brain metastases can benefit from this combination therapy. The safety profile of ABCP was characterized by an acceptable profile with a very low incidence of immune-mediated adverse events. The data obtained allow us to consider ABCP combination therapy an effective strategy for the treatment of advanced NSCLC.

Keywords:

non-small cell lung cancer
one-year mortality
real clinical practice
chemoimmunotherapy
atezolizumab

Authors:

Isaeva G.K.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Andrievskih M.I.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Berseneva O.V.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Shubina K.A.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Taskina D.K.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Erygina A.A.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Maltseva V.A.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Bakhareva I.V.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Menshchikov D.V.

Chelyabinsk Regional Clinical Oncology Center;
South Ural State Medical University

Received:

20.05.2025

Accepted:

10.06.2025

Close metadata

References:

  1. WHO. IARC. Cancer today. 2022. Available at: https://gco.iarc.who.int/today
  2. Kaprin AD, Starinskii VV, Shakhzadova AO, eds. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2020 godu. Moscow: MNIOI im. PA. Gertsena — filial FGBU «NMITS radiologii» Ministerstva zdravookhraneniya Rossiiskoi Federatsii; 2020. (In Russ.).
  3. The Ministry of Health of the Russian Federation. Clinical recommendations. Malignant neoplasms of the bronchi and lungs. 2022. (In Russ.).
  4. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391-400.  https://doi.org/10.1038/nrd1381
  5. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567.  https://doi.org/10.1038/nature14011
  6. Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One. 2009;4(11):e7669. https://doi.org/10.1371/journal.pone.0007669
  7. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2(7):632-642.  https://doi.org/10.1158/2326-6066.CIR-14-0053
  8. Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139-148.  https://doi.org/10.1084/jem.20140559
  9. Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624. https://doi.org/10.1038/ncomms12624
  10. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492-1504. https://doi.org/10.1093/annonc/mdw217
  11. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.  https://doi.org/10.1016/j.immuni.2013.07.012
  12. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39(1):74-88.  https://doi.org/10.1016/j.immuni.2013.06.014
  13. Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52(Pt. 2):117-124.  https://doi.org/10.1016/j.semcancer.2017.12.002
  14. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096-1103. https://doi.org/10.1038/nm1096-1096
  15. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol. 1998;160(3):1224-1232.
  16. Blank C, Mackensen A. Contribution of the PD-L1/PD-1pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739-745.  https://doi.org/10.1007/s00262-006-0272-1
  17. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy — inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580-6587. https://doi.org/10.1158/1078-0432.CCR-12-1362
  18. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071-1121. https://doi.org/10.1152/physrev.00038.2010
  19. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607-615.  https://doi.org/10.1038/nm.3541
  20. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.  https://doi.org/10.1038/nri2506
  21. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475(7355):226-230.  https://doi.org/10.1038/nature10169
  22. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al.; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288-2301. https://doi.org/10.1056/NEJMoa1716948
  23. Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, Mok TSK, Finley G, Aerts JG, Orlandi F, et al. IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol. 2022;17(2):309-323.  https://doi.org/10.1016/j.jtho.2021.09.014
  24. Ikeuchi N, Igata F, Kinoshita E, Kawabata T, Tan I, Osaki Y, Otsuka R, On R, Ikeda T, Nakao A, et al. Real-world efficacy and safety of atezolizumab plus bevacizumab, paclitaxel and carboplatin for first-line treatment of Japanese patients with metastatic non-squamous non-small cell lung cancer. Anticancer Res. 2023;43(2):713-724.  https://doi.org/10.21873/anticanres.16210
  25. Hack SP, Zhu AX, Wang Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities. Front Immunol. 2020;11:598877. https://doi.org/10.3389/fimmu.2020.598877
  26. McCoach CE, Blumenthal GM, Zhang L, Myers A, Tang S, Sridhara R, Keegan P, Pazdur R, Doebele RC, Kazandjian D. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol. 2017;28(11):2707-2714. https://doi.org/10.1093/annonc/mdx414
  27. Morgensztern D, Ko A, O’Brien M, Ong TJ, Waqar SN, Socinski MA, Postmus PE, Bhore R. Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy. Cancer. 2019;125(14):2394-2399. https://doi.org/10.1002/cncr.32114
  28. Besse B, Le Moulec S, Mazières J, Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L, Gervais R, et al. Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res. 2015;21(8):1896-1903. https://doi.org/10.1158/1078-0432.CCR-14-2082
  29. Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Yokoi T, Asao T, Tamiya M, Nakamura A, et al. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: a multicentre, retrospective cohort study. Eur J Cancer. 2021;150:63-72.  https://doi.org/10.1016/j.ejca.2021.03.016
  30. Iwai T, Sugimoto M, Patel H, Yorozu K, Kurasawa M. Kondoh O. Anti-VEGF antibody protects against alveolar exudate leakage caused by vascular hyperpermeability, resulting in mitigation of pneumonitis induced by immunotherapy. Mol Cancer Ther. 2012;20(12):2519-2526. https://doi.org/10.1158/1535-7163.MCT-21-0031
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.